Posted by Michael Wonder on 11 Oct 2021
Medicare drug pricing debate pits savings against innovation
11 October 2021 - Proposal to allow Medicare to negotiate for lower prescription drug prices is central to Democrats’ health care, child care, education and climate package.
Much of the debate on Capitol Hill over whether to allow Medicare to directly negotiate with pharmaceutical companies centers on one question: how government intervention would affect drug makers’ ability to develop new treatments.
